Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy
- PMID: 15693037
- DOI: 10.1002/jgm.713
Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy
Abstract
Recently, it has become more and more obvious that not only CD8+ cytotoxic T lymphocytes, but also CD4+ T helper cells are required for the induction of an optimal, long-lasting anti-tumor immune response. CD4+ T helper cells, and in particular IFN-gamma-secreting type 1 T helper cells, have been shown to fulfill a critical function in the mounting of a cancer-specific response. Consequently, targeting antigens into MHC class II molecules would greatly enhance the efficacy of an anti-cancer vaccine. The dissection of the MHC class II presentation pathway has paved the way for rational approaches to achieve this goal: novel systems have been developed to genetically manipulate the MHC class II presentation pathway. First, different genetic approaches have been used for the delivery of known epitopes into the MHC class II processing pathway or directly onto the peptide-binding groove of the MHC molecules. Second, several strategies exist for the targeting of whole tumor antigens, containing both MHC class I and class II restricted epitopes, to the MHC class II processing pathway. We review these data and describe how this knowledge is currently applied in vaccine development.
Copyright (c) 2005 John Wiley & Sons, Ltd.
Similar articles
-
MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.J Immunother. 2001 May-Jun;24(3):195-204. J Immunother. 2001. PMID: 11394496 Review.
-
Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.Cancer Res. 2003 Sep 1;63(17):5587-94. Cancer Res. 2003. PMID: 14500399
-
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.
-
Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.Eur J Immunol. 2005 Oct;35(10):2826-39. doi: 10.1002/eji.200526299. Eur J Immunol. 2005. PMID: 16163671
-
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review.
Cited by
-
A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma.Dis Markers. 2022 Nov 16;2022:8232024. doi: 10.1155/2022/8232024. eCollection 2022. Dis Markers. 2022. PMID: 36438905 Free PMC article.
-
Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.Cell Mol Life Sci. 2024 Aug 31;81(1):378. doi: 10.1007/s00018-024-05412-y. Cell Mol Life Sci. 2024. PMID: 39215816 Free PMC article. Review.
-
Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):853-70. doi: 10.1177/039463200601900415. Int J Immunopathol Pharmacol. 2006. PMID: 17166407 Free PMC article.
-
Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth.Cell Rep. 2025 Jan 28;44(1):115150. doi: 10.1016/j.celrep.2024.115150. Epub 2025 Jan 2. Cell Rep. 2025. PMID: 39752250 Free PMC article.
-
Targeting lentiviral vectors for cancer immunotherapy.Curr Cancer Ther Rev. 2011 Nov;7(4):248-260. doi: 10.2174/157339411797642605. Curr Cancer Ther Rev. 2011. PMID: 22983382 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials